Moreover, as some recent excellent reviews have described the association of RNA editing with neurodegenerative diseases or current and promising gene therapies for neurodegeneration in general [41,42,43,44], we focused on ALS-related excitotoxicity due to the dysfunction of glutamatergic signaling resulting from dysregulated RNA editing at the GluA2 Q/R site, which are promising future targets in ALS therapy. Here, GRIA2 is linked to amyotrophic lateral sclerosis.